Innate Pharma S.A. (OTCMKTS:IPHYF – Get Rating) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 6,200 shares, a growth of 51.2% from the March 31st total of 4,100 shares. Based on an average daily volume of 500 shares, the days-to-cover ratio is currently 12.4 days.
Shares of Innate Pharma stock opened at $2.75 on Friday. Innate Pharma has a one year low of $2.75 and a one year high of $11.00. The company has a 50-day simple moving average of $3.40 and a two-hundred day simple moving average of $4.27.
Innate Pharma Company Profile (Get Rating)
Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway.
Further Reading
Want More Great Investing Ideas?
Receive News & Ratings for Innate Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Innate Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.
